ClinicalTrials.gg
RecruitingNCT06032494Neo-vitalUpdated Dec 21, 2023

Investigating Changes in Vital Signs in Neonates

An observational study in Infant and Newborn, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged Up to 42 Weeks. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by University of Oxford · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
Up to 42 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Premature Birth by University of Oxford — 3 open to participants now, 4 under way, none of them phase 3. Premature Birth · University of Oxford.

Started
2023
with 1 other
Observational
9 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Premature Birth by University of Oxford, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 9th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

3 of the 11 studies in Premature Birth by University of Oxford are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: Up to 42 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Premature Birth by University of Oxford, or all of them as a file.
02

Study summary

1 in 7 babies require neonatal care. During their time in hospital their vital signs (such as heart rate, breathing rate and oxygen saturation) are continuously monitored as part of standard care. Many factors lead to changes in vital signs, for example, medical procedures such as blood tests can result in brief increases in heart rate. Medication can also alter vital signs, either as an intended effect or as a side effect. However, different infants will respond in different ways to both procedures and medication. Predicting how an individual infant may respond could lead to better individualised care for infants. For example, using an infant's baseline vital signs to predict whether they will experience cardiorespiratory side effects from a particular drug could mean that doctors could choose an alternative safer treatment plan. To develop these predictive models, it is essential to first better understand how infants' vital signs are affected by different procedures and drugs, and how these effects are impacted by other factors such as infection, other pathologies, interaction between drugs and age.

Despite their routine use in hospital neonatal units, detailed electronic records of vital signs are often not recorded. Often, only major events or average values are stated on clinical records. Subtle changes in vital signs are therefore missed, and more complex analysis that may reveal important predictive features within the data is not possible. In this study the investigators will electronically record infant vital signs across longer time periods and during a variety of clinically-necessary procedures and administration of drugs, to explore how these impact vital signs and are altered by factors such as age and pathology. These will be compared with control procedures, such as a nappy change, or when the infant is resting in their cot or receiving skin-to-skin care.

03

Conditions studied

  • Infant
  • Newborn

Browse trials for

Keywords

  • preterm
  • respiration
  • oxygen saturation
  • heart rate
04

Who can participate

Ages eligible
Up to 42 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This single-centre prospective observational exploratory study will take place at the John Radcliffe Hospital, Oxford. Participants will be infants receiving inpatient care on the Newborn Care Unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Infants will be eligible to be included in the study if they are:

  • Born to, or expected to be born to, a mother aged 16 or over
  • Admitted to the Newborn Care Unit, John Radcliffe Hospital, or anticipated delivery of a baby who will require admittance to the Newborn Care Unit at birth
  • Mother given informed written consent

Exclusion criteria

Exclusion Criteria:

Infants will be ineligible if the following exclusion criteria applies:

  • Known chromosomal abnormality or life-threatening congenital abnormality
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in heart rate following drug administration

    To characterise the change in heart rate in infants following drug administration in a wide range of commonly used drugs in neonatal care. Drugs will only be administered as part of clinical care, no drugs are administered for research purposes

    Time frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.

  2. Change in oxygen saturation following drug administration

    To characterise the change in oxygen saturation in infants following drug administration in a wide range of commonly used drugs in neonatal care. Drugs will only be administered as part of clinical care, no drugs are administered for research purposes

    Time frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.

  3. Change in respiratory rate following drug administration

    To characterise the change in heart rate in infants following drug administration in a wide range of commonly used drugs in neonatal care. Drugs will only be administered as part of clinical care, no drugs are administered for research purposes

    Time frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.

  4. Change in heart rate following procedures

    To characterise the change in heart rate in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.

    Time frame: 1 day after procedure, compared with baseline of 1 day before procedure.

  5. Change in oxygen saturation following procedures

    To characterise the change in oxygen saturation in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.

    Time frame: 1 day after procedure, compared with baseline of 1 day before procedure.

  6. Change in respiratory rate following procedures

    To characterise the change in respiratory rate in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.

    Time frame: 1 day after procedure, compared with baseline of 1 day before procedure.

Secondary outcomes

  1. Models of drug response

    Prediction of drug regimen requirements in individual infants from respiratory rate.

    Time frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.

  2. Models of procedure response

    Prediction of procedure outcome in individual infants (e.g. extubation success) from respiratory rate

    Time frame: 1 day after procedure, compared with baseline of 1 day before procedure.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2024, 11 months after the start.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 11 months is below that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Sep 13, 2023
StartActual
Sep 20, 2023
Primary completionEst.
Sep 1, 2024
CompletionEst.
Sep 1, 2024
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06032494
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Sep 20, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Dec 21, 2023

Study contacts

Caroline Hartley, PhD
Contact
caroline.hartley@paediatrics.ox.ac.uk
+44 1865 234537

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion